Siña María Josefina, Valdés Felipe, Zelada Úrsula, Tagle María Teresa, Campillay Rolando, Sandoval Daniela, Herrera Pablo, Bastías Carla
Department of Pediatrics, Immunology Section, Clínica Universidad de los Andes, Santiago, Chile.
Department of Internal Medicine, Immunology Section, Barros Luco Trudeau Healthcare Complex, Santiago, Chile.
Front Allergy. 2023 Feb 1;3:951323. doi: 10.3389/falgy.2022.951323. eCollection 2022.
Nonsteroidal anti-inflammatory exacerbated respiratory disease (N-ERD) is characterized by the Samter triad: chronic rhinosinusitis with nasal polyps, asthma, and nonallergic hypersensitivity to NSAIDs. Its diagnosis is based on a complete clinical history and an aspirin (ASA) challenge test. Medical treatments include biological drugs and ASA desensitization.
This study aims to evaluate the clinical response of patients with N-ERD undergoing functional endoscopic surgery (FES), followed by ASA desensitization and maintenance treatment, being the first prospective cohort study carried out in Chile.
We conducted 1-year follow-up of 12 patients with N-ERD treated with FES, desensitization, and maintenance with ASA. For each control, the medication score, sinonasal symptomatology (SNOT-22), PEF (peak expiratory flow), nasal polyposis (Lildholdt score), and the appearance of adverse effects were recorded. Computed tomography (CT) of the paranasal cavities was performed at baseline and at the 12-month follow-up to calculate the Lund-Mackay score.
Patients presented a reduction of SNOT-22 after the FES, which was maintained at 12 months ( = 0.002); the symptoms that showed the greatest reduction were feeling embarrassed and nasal obstruction. The Lildholdt score was also significantly reduced ( = 0.001); in only three patients, the nasal polyps recurred, and all were small. The PEF showed a slight nonsignificant increase of 3.3%. In total, 75% of patients had an adverse effect, the most frequent being abdominal pain (66.7%), but none of the 12 patients required discontinuation of aspirin treatment in 1-year follow-up. The Lund-Mackay score had a significant reduction of 6.6 points ( < 0.001).
ASA desensitization is safe and effective in reducing upper and lower respiratory symptoms in patients with N-ERD and delays the reappearance of nasal polyps, although it is not exempt from adverse effects, with the vast majority being mild
非甾体抗炎药加重性呼吸系统疾病(N-ERD)的特征为桑特三联征:伴有鼻息肉的慢性鼻-鼻窦炎、哮喘以及对非甾体抗炎药的非过敏性超敏反应。其诊断基于完整的临床病史和阿司匹林(ASA)激发试验。药物治疗包括生物制剂和ASA脱敏治疗。
本研究旨在评估接受功能性鼻内镜手术(FES)、随后进行ASA脱敏和维持治疗的N-ERD患者的临床反应,这是在智利开展的第一项前瞻性队列研究。
我们对12例接受FES、脱敏和ASA维持治疗的N-ERD患者进行了为期1年的随访。每次复查时,记录用药评分、鼻-鼻窦症状(SNOT-22)、呼气峰值流速(PEF)、鼻息肉情况(Lildholdt评分)以及不良反应的出现情况。在基线和12个月随访时进行鼻窦计算机断层扫描(CT)以计算Lund-Mackay评分。
患者在FES后SNOT-22评分降低,并在12个月时保持(P = 0.002);降低最明显的症状是感到窘迫和鼻塞。Lildholdt评分也显著降低(P = 0.001);仅3例患者鼻息肉复发,且均为小息肉。PEF显示轻微的、无统计学意义的3.3%的升高。总共75%的患者出现不良反应,最常见的是腹痛(66.7%),但在1年随访中12例患者均无需停用阿司匹林治疗。Lund-Mackay评分显著降低6.6分(P < 0.001)。
ASA脱敏在减轻N-ERD患者的上、下呼吸道症状以及延迟鼻息肉复发方面安全有效,尽管无法避免不良反应,且绝大多数不良反应为轻度。